Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has emerged as optimal treatment for diffuse malignant peritoneal mesothelioma (DMPM) showing median survivals of 36–92 months. However, recurrences occur frequently even in patients undergoing optimal cytre...
Saved in:
Main Authors: | Lana Bijelic, O. Anthony Stuart, Paul Sugarbaker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/890450 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hyperthermic Intraperitoneal Chemotherapy with Melphalan: A Summary of Clinical and Pharmacological Data in 34 Patients
by: Lana Bijelic, et al.
Published: (2012-01-01) -
Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
by: Yasuo Otsuka, et al.
Published: (2023-01-01) -
Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival
by: Lana Bijelic, et al.
Published: (2012-01-01) -
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO
by: Job P van Kooten, et al.
Published: (2022-06-01) -
Malignant Peritoneal Mesothelioma: Clinicopathological Characteristics of Two Cases
by: Mustafa Cem Algın, et al.
Published: (2014-01-01)